Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Inclusion Criteria: * Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures; * Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and 39, inclusive, is preferred * Subject must meet the criteria of mildly or moderately impaired renal function or have normal renal function * Subject with renal impairment must have evidence of stable disease * If on medications for treatment of the complications of renal disease, and other concommitant chronic illnesses, subject must have been taking the medications at a stable dose for at least 10 days prior to the first Proellex® dosing date and are then to be continued at the same dose for the duration of the study. * Negative urine pregnancy test at screening visit * Subject must agree to use a medically acceptable and effective non-hormonal double barrier method of birth control * Healthy subject must have no significant abnormal findings at the screening physical examination * Subject is willing to remain in the clinic for the screening visit (approximately 1 day for the first screening visit) and for the treatment visit (approximately 3 days) * Additional inclusion criteria may apply Exclusion Criteria: * Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant * Subject with clinically significant abnormal liver function * Pregnant or lactating females, or women who are attempting or expecting to become pregnant at any time during the study or one month after the study * An acute illness within five (5) days of study medication administration * Subject with diagnosed or suspected carcinoma of the breast, reproductive organs or any other organ system * Additional exclusion criteria may apply